cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Nurhadiyahya
Contact Email
nurhadiyahya@ugm.ac.id
Phone
+6289672800034
Journal Mail Official
ijpther@ugm.ac.id
Editorial Address
Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada Jl. Farmako Sekip Utara, Yogyakarta 55281
Location
Kab. sleman,
Daerah istimewa yogyakarta
INDONESIA
Indonesian Journal of Pharmacology and Therapy
Published by Universitas Gadjah Mada
ISSN : -     EISSN : 2745455X     DOI : https://doi.org/10.22146/ijpther.4468
Core Subject : Science,
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Neuroscience
Indonesian Journal of Pharmacology and Therapy (IJPTher ) is a scientific journal which managed by Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada. IJPTher is an open-access, and double-blind peer-reviewed journal published twice Issues a year. IJPTher aims to communicate high-quality articles in the fields of pharmacology. IJPTher publishes original articles, review articles, case reports and book reviews in the fields of pharmacology including basic pharmacology, clinical pharmacology, pharmacotherapy, pharmacoepidemiology, pharmacogenetics, pharmacogenomics, pharmacoeconomic, toxicology and toxicogenomics.
Arjuna Subject : Pharmacology, Toxicology and Pharmaceutics - Pharmacology, Toxicology and Pharmaceutics (Lain-Lain)
Articles 5 Documents
 1 
Search results for , issue "Vol 4 No 1 (2023)" : 5 Documents clear
Safety profile between fluoxetine and sertraline as antidepressants for pregnant women with depression disorder Dewa Ayu Sri Handani; Maria Sri Ayu Mustikawati; Ni Putu Parwatininghati; Zulkarnaen; Jusnita Akuba
Indonesian Journal of Pharmacology and Therapy Vol 4 No 1 (2023)
Publisher : Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (211.097 KB) | DOI: 10.22146/ijpther.3237

Abstract

Depression disorders are common in women of productive age, especially during pregnancy and peripartum period. Making a decision on the choosing of antidepressants is associated to the biggest concern about the risk of birth defects and major anomalies of their exposure. Decisions of antidepressant use not only involve considering the risks of medications exposure, but also the risks of untreated depression during pregnancy. Evaluation of the safety profile of selective reuptake inhibitors (SSRIs) which are commonly prescribed during pregnancy therefore urgently needed. This review aimed to compare two widely used SSRIs i.e. fluoxentine and sertraline as antidepressants for pregnant women with depression disorder. It is found that sertraline has more positive effects and more safe. Sertraline is well tolerated in pregnant women and breastfeeding mothers with depression disorder.
Asthma in pregnant woman and its management : a review Farni Yuliana Pratiwi; Hadiatussalamah; Intan Adevia Rosnarita; Yuda Anzas Mara; Novia Ariani Dewi
Indonesian Journal of Pharmacology and Therapy Vol 4 No 1 (2023)
Publisher : Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (424.821 KB) | DOI: 10.22146/ijpther.3239

Abstract

Asthma is the most common comorbidity in pregnant women and gives 30% of exacerbation experience. The other 30% will see improvement of their symptoms, and the rest will not see the changes. Exacerbations have become a major clinical concern in pregnant women. Medical concerns for the mother and the childbirth included low birth weight, preeclampsia, and preterm delivery. The major goal is to keep asthma under control to ensure mother's health and well-being, as well as fetal growth. Controlling asthma and preventing exacerbations are the main goals of asthma treatment during pregnancy. Treatment for asthma should ideally begin before conception. This is to avoid day-time and night-time symptoms, as well as to keep lung function. Furthermore, fetal oxygenation is a crucial factor during the pregnancy. With a few exceptions, asthma drugs are basically the same in pregnancy as they are in non-pregnant people. Inhaled corticosteroids (ICS) are often used as a controlling treatment. Budesonide is the recommended ICS. Short-acting β-agonist (SABA) preferable as reliever in acute asthma and to relieve exacerbation. As an add-on therapy for medium to high dose ICS, long-acting β-gonists (LABA) is often used. Virus infections and ICS nonadherence are the two most common causes of asthma exacerbations during pregnancy.
Comparison between metformin and glibenclamide as antidiabetic oral in gestational diabetes mellitus: a review Firda Ridhayani; I Dewa Agung Ayu Diva Candraningrat; Ilmi Nurhafizah; Karina Nurlitasari; Mardiana Siregar
Indonesian Journal of Pharmacology and Therapy Vol 4 No 1 (2023)
Publisher : Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (235.088 KB) | DOI: 10.22146/ijpther.5867

Abstract

Gestational diabetes mellitus (GDM) is one of the most frequent clinical complications during pregnancy that affects up to 6% of women with pregnancies around the world. Gestational diabetes mellitus treatment used insulin as first-line therapy. In addition, several professional associations are also considering treatment using antidiabetic oral which has equivalent efficacy compared with insulin. However, many oral antidiabetic recommendations have been administered to treat GDM, including metformin and glyburide or glibenclamide. This article’s review aims to compare the usage between metformin and glyburide or glibenclamide in GDM patients. This review compared research results from PubMed as literature resources and the PRISMA flow chart as the protocol for the article selection process. Based on inclusion and exclusion criteria there are six research articles that are appropriate to the article’s topic and aim. Metformin is superior compared with glyburide or glibenclamide administration as antidiabetic oral in GDM. Metformin showed a significant effect in lowering preprandial and postprandial glucose level, elevating insulin sensitivity, while glibenclamide administration decreased dynamic pancreatic β-cell responsivity significantly and had a higher risk compared with insulin and metformin.
Adverse events following immunization (AEFIs) in health workers who receive COVID-19 vaccination at Academic Hospital Universitas Gadjah Mada, Yogyakarta Ade Febrina Lestari; Mei Neni Sitaresmi; Anjarsari Haspitaningrum; Kusuma Ayu Rachmasari; Ratih Wulandari; Shinta Kusumalarna Sari; Firda Ridhayani
Indonesian Journal of Pharmacology and Therapy Vol 4 No 1 (2023)
Publisher : Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (269.63 KB)

Abstract

COVID-19 is a new viral infection that has become a global pandemic, resulting in extremely high mortality and morbidity rates worldwide, including in Indonesia. Vaccination is one of the strategies for preventing COVID-19 infection promoted by the World Health Organization (WHO) to reduce COVID-19 morbidity and mortality. The Indonesian government supports the implementation of vaccination and conducts mass vaccination as a strategy to overcome the pandemic in Indonesia. The high immunization coverage resulted in increased use of vaccines, and events following immunization (AEFI) also increased. Reports on follow-up AEFI are needed as government policy references and information for the public. This study aims to describe the following events after the COVID-19 vaccine immunization and the incidence of the infection post vaccination. The study design was a cross-sectional study using primary and secondary data. The data were analyzed descriptively and statistically using Chi Square method by identifying association between demographic data and AEFI incidence. A total 131 respondents were included. Most respondents experienced AEFI after giving the first (77.1%) or second (71.9%) vaccine with the Sinovac vaccine. However, all reported mild AEFI. Most reported AEFIs were pain (48.8% and 49.6%), hungry (37.4% and 10.0%), and drowsiness (32.1% and 23.7%) after the first and the second vaccine. In conclusion, the prevalence of AEFI in the first and the second dose of inactivated COVID-19 vaccine is higher than that reported in the clinical trial study although the all AEFIs are considered as mild.
Safety monitoring of chloroquine and hydroxychloroquine in COVID-19 patients in Indonesia on QT prolongation: hospital based monitoring study Jarir At Thobari; Togi Junice Hutadjulu; Tri Asti Isnariani; Umi Sa'adatun Nikmah; Lukman Ade Chandra; Pompini Agustina Sitompul; Anggoro Budi Hartopo; Rizki Amalia Gumilang; Luhur Pribadi; Deva Bachtiar; Anwar Santoso
Indonesian Journal of Pharmacology and Therapy Vol 4 No 1 (2023)
Publisher : Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (287.561 KB) | DOI: 10.22146/ijpther.7148

Abstract

Chloroquine (CQ) and Hydroxychloroquine (HCQ) are the challenging drugs used for COVID-19. Several studies show its beneficial, however, both medications can prolong the QTc interval and increase the risk of patients for torsades de pointes and death. The Tisdale score is identified to have successfully predicted the at-risk population of side effects of these drugs. This study aim to evaluate the QT prolongation caused by the administration of chloroquine and hydroxychloroquine in COVID-19 patients and the association with the treatment outcomes based on their Tisdale score. We conducted an observational study on 213 hospitalized patients with confirmed or suspect COVID-19 in 6 referral hospitals in Indonesia. All baseline demographic such as age and gender, RT-PCR test result, severity of disease, history of cardiovascular disease (myocardial infarction, heart failure, hypertension), serum kalium level at baseline, and the use of medication associated with risk QTc interval prolongation were collected. The Tisdale risk score was used for predicting high-risk patients for QT corrected (QTc) interval prolongation. Out of 213 patients who were treated with CQ/HCQ, there were 60 (28.2%) patients had QTc interval prolongation, included 43 patients (20.2%) who had normal QTc interval at baseline and at the end of treatment had prolong interval; or 17 patients (8.0%) who had QTc interval more than 470 msec at baseline and QTc interval prolongation was worsen at the end of treatment. Several factors, including age more than 50 years, COVID-19 confirm PCR, and had comorbidity heart failure, were statistically significant associated with QTc interval prolongation. The high-risk score of Tisdale score have increased risk significantly on QTc interval prolongation (RR: 2.15, 95%CI 1.07-4.32) and associated with risk of death (RR: 3.50, 95%CI 1.34-9.13) compared to low-risk score. Our findings showed that the treatment of CQ/HCQ in COVID-19 patients is associated with QTc prolongation. The Tisdale score can be used as a valuable tool to predict the COVID-19 patients’ outcome after treatment of these QTc-prolonging drugs.

Page 1 of 1 | Total Record : 5

 1 

Filter by Year

2023 2023


Reset
Filter By Issues
All Issue Vol 4 No 2 (2023) Vol 4 No 1 (2023) Vol 3 No 3 (2022) Vol 3 No 2 (2022) Vol 3 No 1 (2022) Vol 2 No 3 (2021): Special Issue: COVID-19 Vol 2 No 3 (2021) Vol 2 No 2 (2021) Vol 2 No 1 (2021) Vol 1 No 2 (2020) Vol 1 No 1 (2020) More Issue